Luxturna gets EU approval

The European Commission approved Luxturna voretigene neparvovec to treat patients with vision loss due to genetic mutation in both copies of the retinal pigment epithelium-specific protein 65kDa (RPE65) gene and who have enough viable retinal cells.

Novartis AG (NYSE:NVS; SIX:NOVN) has ex-U.S. rights to Luxturna from Spark Therapeutics Inc. (NASDAQ:ONCE) (see "Novartis Gains ex-U.S. Rights to Spark's Gene Therapy")...